Phage therapy case reveals hidden antibodies can block treatment of drug-resistant infections

A new treatment for patients with life-threatening infectious diseases is being pioneered in Melbourne by researchers at The Alfred and Monash University. VICPhage, a clinical partnership between The Alfred and Monash, is one of the first in Australia to offer end-to-end capacity in phage therapy to treat some of the most challenging infections.